HR+/HER2- accounts for roughly 68% of US breast cancers, but the commercially decisive population is the 20-30% who progress to metastatic disease, where five-year relative survival is about 32%.
Breast cancer is the most common non-skin cancer in US women, with the American Cancer Society estimating roughly 317,000 new invasive female cases in 2025. Hormone receptor-positive, HER2-negative disease (ER and/or PR positive, HER2 not overexpressed) is the dominant molecular subtype at approximately 68% of cases per SEER. The overwhelming majority present as early-stage, endocrine-sensitive disease that is treated with surgery, radiation and adjuvant endocrine therapy and is largely curable. Only about 6% present as de novo stage IV. The metastatic population that drives the systemic-therapy market is built mainly from the estimated 20-30% of early-stage patients who later recur, often years after diagnosis.
In the metastatic setting the clinical pathway is defined by biomarker testing layered on top of standard ER/PR/HER2 immunohistochemistry. First line is endocrine therapy (aromatase inhibitor or fulvestrant) plus a CDK4/6 inhibitor. At progression, molecular testing on tissue or circulating tumor DNA directs the next line: ESR1 mutations (detected in ~48% of CDK4/6-pretreated patients in EMERALD) open the door to the oral SERD elacestrant; PIK3CA mutations (~40% of HR+/HER2- disease per SOLAR-1) direct patients to alpelisib; AKT-pathway alterations direct patients to capivasertib. This makes serial genomic testing, not a single line of therapy, the structural feature of the HR+/HER2- metastatic pathway.
The HR+/HER2- funnel: from ~317,000 US cases to a biomarker-segmented metastatic population.
| Parameter (US) | Value | Source |
|---|---|---|
| New invasive female breast cancer cases, 2025 | ~316,950 | ACS Cancer Facts & Figures 2025 |
| HR+/HER2- share of breast cancers | ~68% | SEER (US) |
| Presenting as de novo metastatic (stage IV) | ~6% | SEER (US) |
| Early-stage patients who later recur to metastatic | ~20-30% | NCCN Breast Cancer guideline / clinical literature |
| 5-year relative survival, distant (metastatic) stage | ~32% | SEER (US) |
| PIK3CA mutation prevalence (HR+/HER2-) | ~40% | SOLAR-1 (PMID 31091374) |
| ESR1 mutation prevalence (CDK4/6-pretreated) | ~48% | EMERALD (PMID 35584336) |
Sources: US epidemiology: American Cancer Society Cancer Facts & Figures 2025 (incidence); SEER (subtype share, de novo metastatic fraction, distant-stage 5-year relative survival). Biomarker prevalence: PIK3CA ~40% from SOLAR-1 (PMID 31091374, verified live via PubMed); ESR1 ~48% among CDK4/6-pretreated from EMERALD (PMID 35584336, verified live). Pathway: NCCN Breast Cancer Clinical Practice Guidelines.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Incidence funnel: new cases -> HR+/HER2- share -> de novo stage IV plus recurrences • Distant-stage survival that sizes the treated-and-retreated pool
Delivers
- • ER/PR/HER2 at diagnosis
- ESR1 and PIK3CA at progression • Tissue vs ctDNA testing and prevalence of each mutation
Delivers
- • Curative adjuvant endocrine +/- CDK4/6 in early disease • Sequential, non-curative, biomarker-directed lines in metastatic disease
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why ER/PR-positive, HER2-negative disease at approximately 68% of cases (SEER) defines the treatment paradigm for the whole indication
- How endocrine sensitivity shapes early-stage curative intent versus the metastatic, biomarker-directed treatment pathway
- Why only about 6% of the roughly 317,000 annual US invasive cases (ACS 2025) present as stage IV at initial diagnosis, per SEER
- How the incidence funnel from new diagnosis to HR+/HER2- share to de novo metastatic status sizes the immediately addressable population
- Why the estimated 20-30% of early-stage patients who later recur, not de novo cases, builds most of the metastatic treatment pool
- How a multi-year latency between early-stage treatment and eventual recurrence shapes the timing of the systemic-therapy market
- Why an aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor is standard first line before any ESR1 or PIK3CA testing occurs
- How first-line treatment intent differs from the serial genomic testing that governs every subsequent line of therapy
- Why ESR1 mutations, found in roughly 48% of CDK4/6-pretreated patients in EMERALD, open access to elacestrant
- How PIK3CA mutations, present in about 40% of HR+/HER2- disease per SOLAR-1, route patients to alpelisib instead
- Why the roughly 32% five-year relative survival at distant stage (SEER) defines the ceiling every sequencing strategy fights against
- How serial genomic testing, not a single line of therapy, becomes the structural feature once patients reach this survival wall
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Breast Cancer HR+/HER2- Disease Landscape sources: American Cancer Society, SEER, NCCN guidelines, and primary trial publications for biomarker prevalence.
- PIK3CA mutations occur in approximately 40% of HR+/HER2- breast cancer, per SOLAR-1 (PubMed PMID 31091374)
- ESR1 mutation detected in 47.8% of CDK4/6-pretreated patients screened for EMERALD (PMID 35584336)
- HR+/HER2- share (~68%), de novo metastatic (~6%) and distant-stage 5-year survival (~32%) from SEER (US); marked as SEER-sourced, not PubMed
- 2025 US invasive female incidence (~316,950) from ACS Cancer Facts & Figures 2025; marked as ACS-sourced, not PubMed
Frequently asked questions
Commission this assessment
AXLRx delivers US Breast Cancer HR+/HER2- disease landscape built for pharma and biotech commercial, access, and medical affairs teams. Custom assessment in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.